Study Summaries - GYOEDU Plus (Page 4)

Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer: EORTC Trial

Neoadjuvant chemotherapy followed by interval debulking surgery is not inferior to primary debulking surgery followed by chemotherapy in patients with bulky stage IIIC or IV ovarian carcinoma. Complete resection of all macroscopic disease remains the objective in cytoreductive surgery.

Early Stage Ovarian Cancer Trials List

ACTION Trial - Early Stage Ovarian 10 year

Completeness of surgical staging is a significant prognostic factor, with better outcomes observed in optimally staged patients. Adjuvant chemotherapy benefits appear restricted to nonoptimally staged patients.

Tisotumab in Cervical Cancer: InnovaTV 204/ GOG-3023/ENGOT-cx6 Phase 2 trial

Tisotumab vedotin showed clinically meaningful and durable antitumor activity with a manageable and tolerable safety profile in women with previously treated recurrent or metastatic cervical cancer.

GOG 240: Bevacizumab in Advanced Cervical Cancer

The addition of bevacizumab to combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer improved median overall survival by 3.7 months and was associated with higher response rates.

Tata Memorial Hospital Trial: Neoadjuvant Chemo + Surgery vs. ChemoRT

Cisplatin-based concomitant chemoradiation resulted in superior DFS compared to neoadjuvant chemotherapy followed by radical surgery in patients with locally advanced cervical cancer.

UTERUS-11: Surgical versus clinical staging before primary chemoradiation

GROINS V II: Radiotherapy Versus Inguinofemoral Lymphadenectomy

Inguinofemoral radiotherapy is a safe alternative for IFL in patients with SN micrometastases, showing minimal morbidity. However, for patients with SN macrometastasis, radiotherapy alone resulted in more isolated groin recurrences compared to IFL.

GOG 92: Sedlis Criteria Study

Adjuvant pelvic radiotherapy significantly reduces the risk of cancer recurrence in women with Stage IB cervical cancer who have undergone radical hysterectomy and pelvic lymphadenectomy and possess specific high-risk factors. The treatment is associated with higher but acceptable morbidity.